David Arkowitz News Today

See which leaders are on the move across the pharma, biotech and medical marketing industries.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Kevin Mannix, Head of Investor Relations. Please go ahead. Kevin Mannix: […]

Operator: Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

Seres, together with partners Nestle Health Science, receive approval for its microbiome therapeutic to prevent recurrence of C. difficile infection.

Seres Therapeutics, a leading microbiome therapeutics company, entered into a new $250 million senior secured debt facility ("Term Loan Facility") provided by funds managed by Oaktree Capital Management. The Company drew the first tranche of $110 million at closing, with three additional tranches available. These additional tranches include $90...

On July 7, 2022, invoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) commenced a cash tender offer for all of the issued and

Operator Good afternoon, ladies and gentlemen. And welcome to the Flexion Therapeutics First Quarter 2021 Financial Results Conference Call. [Operator Instructions] We will be facilitating a question-and-answer session at the end of todays call. [Operator Instructions] Ill now turn the call over to Scott Young, Flexions Vice President of Corporate Communications and Investor Relations. Scott Young -- Vice President of Corporate Communications & Investor Relations Good afternoon. A short while ...

Flexion Therapeutics Inc (FLXN) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Flexion Therapeutics Inc (NASDAQ: FLXN) Popular Searches Operator Good afternoon, ladies and gentlemen, and welcome to the Flexion Therapeutics Business Update Call. [Operator Instructions] I will now turn the call over to Scott Young, Flexions Vice President of Corporate Communications and Investor Relations.SPONSORED: 10 stock...

Share: Shares of Yumanity to commence trading on Nasdaq under new ticker symbol "YMTX" on December 23, 2020 $33.6 million common stock private investment in public equity ("PIPE") transaction closes concurrently with the merger BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ:YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that its revers...